Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 4:30 PM
Ignite Modification Date: 2025-12-24 @ 4:30 PM
NCT ID: NCT00660166
Eligibility Criteria: Inclusion Criteria: * Patients who have undergone an autologous stem cell transplant for the following diseases: * Acute Myeloid Leukemia * Non-Hodgkin's Lymphoma * Hodgkin's Disease * Multiple Myeloma * Age 13 - 70 years old * Able to give informed consent * Hepatic and renal function: bilirubin less than or equal to 2x normal limits, AST and ALT less than or equal to 2x normal limits, serum creatinine less than or equal to 1.5x normal * ECOG Performance Status less than or equal to 1 (at planned time of transplantation) * Patients with no active infection Exclusion Criteria: * Patients who have not recovered sufficiently from the side effects of the autologous transplant (i.e. have \> grade 2 toxicity in any organ system) * Patients who have insufficient engraftment parameters according to the following criteria: WBC \< 2,500 /mm3 and platelets \< 50,000/mm3 * Radiation therapy, chemotherapy, or immunotherapy beginning one week before NK-cell infusion and lasting 2 weeks after NK-cell infusion. * Intrinsic impaired organ function (as stated above). * Physical or psychiatric conditions that in the estimation of the PI or designee place the patient at high-risk of toxicity or non-compliance. * Uncontrolled, life-threatening infections at the time of infusion. * Concurrent treatment with corticosteroids and/or other immuno-suppressive drugs.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 13 Years
Maximum Age: 70 Years
Study: NCT00660166
Study Brief:
Protocol Section: NCT00660166